A meta-analysis of randomized controlled trials on statins for the prevention of contrast-induced acute kidney injury in patients with and without acute coronary syndromes.

[1]  Jeffrey M Schussler,et al.  Contrast-induced acute kidney injury. , 2018, Journal of the American College of Cardiology.

[2]  S. Villani,et al.  Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). , 2014, Journal of the American College of Cardiology.

[3]  R. Mehran,et al.  Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. , 2014, Journal of the American College of Cardiology.

[4]  H. Cong,et al.  Effect of short-term different statins loading dose on renal function and CI-AKI incidence in patients undergoing invasive coronary procedures. , 2013, International journal of cardiology.

[5]  P. Libby.  Mechanisms of acute coronary syndromes and their implications for therapy. , 2013, The New England journal of medicine.

[6]  A. Colombo,et al.  Impact of a High Loading Dose of Atorvastatin on Contrast-Induced Acute Kidney Injury , 2012, Circulation.

[7]  Xiangnan Li,et al.  Beneficial Effects of High-Dose Atorvastatin Pretreatment on Renal Function in Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Emergency Percutaneous Coronary Intervention , 2012, Cardiology.

[8]  W. Yuan,et al.  Short-term, high-dose statins in the prevention of contrast-induced nephropathy: a systematic review and meta-analysis. , 2011, Clinical nephrology.

[9]  Ya‐wei Xu,et al.  High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis. , 2011, The Canadian journal of cardiology.

[10]  V. Pasceri,et al.  Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] tria , 2011, The American journal of cardiology.

[11]  S. Weisbord,et al.  Contrast-induced acute kidney injury: short- and long-term implications. , 2011, Seminars in nephrology.

[12]  Linghong Shen,et al.  Statins for the Prevention of Contrast-Induced Nephropathy: A Systematic Review and Meta-Analysis , 2011, American Journal of Nephrology.

[13]  K. Yun,et al.  12-month follow-up results of high dose rosuvastatin loading before percutaneous coronary intervention in patients with acute coronary syndrome. , 2011, International journal of cardiology.

[14]  A. Yıldırır,et al.  Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography , 2010, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[15]  Volkmar Falk,et al.  Guidelines on Myocardial Revascularization the Task Force on Myocardial Revascularization of the European Society of Cardiology (esc) and the European Association for Cardio-thoracic Surgery (eacts) Developed with the Special Contribution of the European Association for Percutaneous Cardiovascular I , 2022 .

[16]  Volkmar Falk,et al.  Guidelines on myocardial revascularization. , 2010, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[17]  M. Aydın,et al.  Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. , 2010, Angiology.

[18]  T. Iwasaka,et al.  Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome. , 2010, The American journal of cardiology.

[19]  R. Mehran,et al.  Evidence‐based management of patients undergoing PCI: Contrast‐induced acute kidney injury , 2010, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[20]  M. Leoncini,et al.  Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. , 2010, The American journal of cardiology.

[21]  Eun Mi Lee,et al.  The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. , 2009, International journal of cardiology.

[22]  Jia Xinwei,et al.  Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. , 2009, The American journal of cardiology.

[23]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[24]  P. Gargiulo,et al.  Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175 634 patients , 2009, Journal of hypertension.

[25]  E. Jaimes,et al.  Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability. , 2008, American journal of physiology. Renal physiology.

[26]  Yong-Jin Kim,et al.  Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial--a randomized controlled study. , 2008, American heart journal.

[27]  V. Pasceri,et al.  Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. , 2006, Journal of the American College of Cardiology.

[28]  R. Komers,et al.  Renal Effects of HMG-CoA Reductase Inhibition in a Rat Model of Chronic Inhibition of Nitric Oxide Synthesis , 2006, Kidney and Blood Pressure Research.

[29]  P. Parfrey,et al.  Preventing Nephropathy Induced by Contrast Medium , 2006 .

[30]  E. Kline-Rogers,et al.  Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. , 2005, The American journal of medicine.

[31]  T. Gajanayake,et al.  Sirolimus increases tissue factor expression but not activity in cultured human vascular smooth muscle cells , 2005, BMC cardiovascular disorders.

[32]  F. Veglia,et al.  Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. , 2004, Journal of the American College of Cardiology.

[33]  A. Colombo,et al.  Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. , 2004, European heart journal.

[34]  J. Yee,et al.  The potential role of statins in contrast nephropathy. , 2004, Clinical nephrology.

[35]  V. Pasceri,et al.  Randomized Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary Intervention: Results From the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) Study , 2004, Circulation.

[36]  A. M. Leone,et al.  Prothrombotic Response to Coronary Angioplasty in Patients with Unstable Angina and Raised C-Reactive Protein , 2002, Journal of Thrombosis and Thrombolysis.

[37]  C. Napoli,et al.  Statin effects beyond lipid lowering--are they clinically relevant? , 2003, European heart journal.

[38]  D. Haskard,et al.  Statin-Induced Expression of Decay-Accelerating Factor Protects Vascular Endothelium Against Complement-Mediated Injury , 2002, Circulation research.

[39]  S. Fichtlscherer,et al.  Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. , 2001, Journal of the American College of Cardiology.

[40]  K. Takeda,et al.  Downregulation of Angiotensin II Type 1 Receptor by Hydrophobic 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Vascular Smooth Muscle Cells , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[41]  T. Yamashita,et al.  Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. , 2001, Atherosclerosis.

[42]  J. Navarro-Antolín,et al.  Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. , 1998, The Journal of clinical investigation.

[43]  Stephen J. Sharp,et al.  Meta-analysis regression , 1998 .

[44]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[45]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.